Sunshine Biopharma (SBFM) Income from Continuing Operations (2011 - 2026)
Sunshine Biopharma (SBFM) posted Income from Continuing Operations of 1243869.0 for Q1 2026, up 42.52% on a QoQ basis from 2163851.0 in Q4 2025, and down 5.43% year-over-year from 1315332.16 in Q1 2025.
Sunshine Biopharma (SBFM) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Sunshine Biopharma's Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 1243869.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 5.43% year-over-year to 1243869.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6062374.0 (down 2.69% YoY) and the FY2025 annual result came in at 5998276.0, down 8.7% from the prior year.
- Income from Continuing Operations was 1243869.0 for Q1 2026 at Sunshine Biopharma, up from 2163851.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 538872.0 in Q2 2022 and bottomed at 23512315.0 in Q4 2022.
- A 5-year average of 2616112.71 and a median of 1236234.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 3624.47% — and 2023, when it jumped 94.85%.
- Sunshine Biopharma's Income from Continuing Operations stood at 23512315.0 in 2022, then soared by 94.85% to 1211970.0 in 2023, then plunged by 109.77% to 2542307.0 in 2024, then climbed by 14.89% to 2163851.0 in 2025, then jumped by 42.52% to 1243869.0 in 2026.
- Business Quant data shows SBFM's Income from Continuing Operations at 1243869.0 in Q1 2026, 2163851.0 in Q4 2025, and 883820.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | -1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | -883,820.00 |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -1.18 Mn |
| Dec 31, 2024 | -2.54 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -983,796.00 |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -1.21 Mn |
| Sep 30, 2023 | -663,116.00 |
| Jun 30, 2023 | -902,108.00 |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -23.51 Mn |
| Sep 30, 2022 | -1.46 Mn |
| Jun 30, 2022 | -538,872.00 |
| Mar 31, 2022 | -1.24 Mn |
| Dec 31, 2021 | 667,116.00 |
| Sep 30, 2021 | -4.04 Mn |
| Jun 30, 2021 | -2.88 Mn |